I'm a pathologist and an avocational programmer. This is pretty neat material and is very relevant to me, as I have been trying to bone up my math chops with Khan Academy videos so that I can tackle some computer vision related work in pathology.
With regards to the study, I will just point out that the system is not diagnosing breast carcinoma, but rather is producing a score which reflects the prognosis as relates to overall survival of the patient (so it is not as impressive as the somewhat hyperbolic HN title makes it out to be... a better title would be 'Stanford computer analyzes breast cancer more accurately than human doctor' which is not surprising at all given the well-documented interobserver variability in breast cancer scoring, particularly in moderately-differentiated tumors). That is to say that the computer already knows the tissue that it is looking at is a tumor and not benign breast tissue. Furthermore, it is really only providing a histologic (or morphologic) score, which is to say, that it is attempting to predict how aggressive the tumor will behave based upon how well or not well it is differentiated (how ugly it is). These days, this score is actually less useful in clinical practice than other information such as whether or not the tumor cells are expressing estrogen/progesterone hormone receptors, or if it is over-expressing Her2-neu protein, as these are possible paths for cancer therapy (anti-estrogen drugs vs. Herceptin) in addition to being prognostic indicators (tumors which express ER/PR generally behave better than tumors which are ER/PR negative and express Her2), as well as the stage (or how far the cancer has already spread) at the time the patient is diagnosed. There are a bunch of companies which are getting FDA approval for computer vision related algorithms for scoring immunohistochemical assays for ER/PR/Her2 [1].
So I am actually far less concerned about a computer doing my job very well, which is actually looking at a piece of tissue on a slide and making a tumor versus not-tumor distinction. This is very hard to do and I think will continue to be even harder for computers/computer-vision/AI to do for a long time to come. I am far more concerned about molecular diagnostics. That is the true-future for making cancer determinations and may even eliminate the part of my job where I tell you if something is benign vs. malignant.
[1] http://www.aperio.com/pathology-services/analyze-slides-auto...